[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Covid, vaccines, malaria", "description": "I have worked directly with Wefwafwa in rural Uganda, he is the real deal. If you buy him a coffee, he will not spend it on coffee.\n\nBuy me a coffee https://www.buymeacoffee.com/awmedicalvideos\n\nPatreon https://www.patreon.com/awmedicalvideos \n\nTo contact Wefwafwa directly, wefandrew@gmail.com or \n\nWhatsApp+256756320736\n\nYouTube channel, https://www.youtube.com/c/WefwafwaAndrew", "link": "https://www.youtube.com/watch?v=9CairUDsY98", "date_published": "2022-10-27 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Pre vaccine fatality rates", "description": "Lower than previously thought\n\nImpact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand (16th March 2020)\n\nImperial College COVID-19 Response Team \n\nhttps://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf\n\nWe assumed\n\nIncubation period of 5.1 days\n\nInfectious 12 hours before to 4.6 days after\n\nR0=2.4 \n\nNon-uniform attack, applied to the GB population\n\nResult in an IFR of 0.9% \n\nwith 4.4% of infections hospitalised\n\n10.4 day stay\n\n30% of hospitalised, ICU (50% death rate)\n\n(not accounting for the potential negative effects of health systems being overwhelmed on mortality)\n\nAge-stratified infection fatality rate of COVID-19 in the non-elderly informed from pre-vaccination national seroprevalence studies\n\nStanford California, Rome, Montreal\n\nhttps://www.medrxiv.org/content/10.1101/2022.10.11.22280963v1\n\n40 eligible national seroprevalence studies,\n\ncovering 38 countries with pre-vaccination seroprevalence data. \n\nFor 29 countries publicly available age-stratified COVID-19 death data,\n\nand age-stratified seroprevalence information were available,\n\nand were included in the primary analysis. \n\nIFRs for 0 to 59 years\n\nmedian IFR = 0.035%\n\n(IQR, 0.013 - 0.056%)\n\nWithout accounting for seroreversion\n\n(average time from seroconversion to seroreversion at 3-4 months)\n\nIFRs for 0 to 69 years\n\nIFR = 0.095% \n\n0 to 19 years\n\nIFR = 0.0003%\n\n20 to 29 years\n\nIFR = 0.003%\n\n30 to 39 years\n\nIFR = 0.011%\n\n40-49 years\n\nIFR = 0.035% \n\n50-59 years\n\nIFR = 0.129%\n\n60-69 years\n\nIFR = 0.501%\n\nAt a global level\n\nPre-vaccination IFR,\n\nmay have been as low as,\n\n0 to 59 years = 0.03%\n\n0 to 69 years = 0.07%\n\nGlobal population\n\n94% younger than 70 years\n\n91% younger than 65 years\n\n86% younger than 60 years\n\nThe current analysis suggests a much lower pre-vaccination IFR in non-elderly populations than previously suggested. \n\nLarge differences did exist between countries and may reflect differences in comorbidities and other factors. \n\nThese estimates provide a baseline from which to fathom further IFR declines with the widespread use of,\n\nVaccination \n\nPrior infections\n\nEvolution of new variants.\n\nUnmitigated epidemic\n(March 2020)\nUK deaths = 510,000 (168,913)\n\nUS deaths =  2.2 million (1,065,152)\n\nDuring 2021 and 2022\n\nVaccination, new variants, prior infections,\n\nresulted in a marked decline in the IFR", "link": "https://www.youtube.com/watch?v=GxsD1UbVhGw", "date_published": "2022-10-27 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]